Document:

STEM CELL THERAPY INTERNATIONAL, INC.

              SCTI MEDICAL AND SCIENTIFIC ADVISORY BOARD AGREEMENT

     THIS  AGREEMENT is made this 10th day of October, 2005, by and between STEM
CELL THERAPY INTERNATIONAL, INC.; a corporation duly incorporated under the laws
of Nevada, with its principal office located at 2203 North Lois Ave., 9th Floor,
Tampa,  Florida 33594 ("the Company''), and DR. WEIWEN DENG, MD., as a member of
the  SCTI  Medical  and  Scientific  Advisory  Board,  herein  ("the  Advisor").

     In  consideration  of the mutual agreements contained in this document, the
parties,  intending  to  be  legally  bound,  agree  as  follows:

 1.     INDEPENDENT  CONTRACTOR.

     The  Advisor  will  be an independent contractor and not an Employee of the
Company  and  will  determine  will  determine  the  method  of operation in the
performance  of  allo  (human)  stem  cell  biological  solution  and  tissue
transplantations  and/or  any  other  type of required stem cell transplantation
therapy.

     The  Advisor  will not be entitled to receive any compensation, commissions
or  benefits  other  than  those  expressly  provided  in  this  Agreement.

 2.     SCOPE  OF  DUTIES.

(a)     The  Advisor  certifies  that  there  are  no  outstanding agreements or
obligations  that conflict with any of the provisions of this Agreement, or that
would  preclude  or  in  any  way  compromise the Advisor in compliance with the
provisions  hereof.

(b)     The  Advisor agrees to actively participate in the Company's Medical and
Scientific  Advisory Board and to review patient's medical charts and records as
provided  by  the  Company and to provide the Company a written report detailing
recommendations  for  the  appropriate  course  of  stem cell therapy treatment.

(c)     The  Advisor agrees to participate in conference calls and meetings with
the  SCTI  Corporate  Officers  and  other  members of the Company's Medical and
Scientific  Advisory  Board  when his/her schedule allows, to discuss the latest
technology  in  stem  cell  treatments  and  shall  contribute  with  his/her
recommendations  on  future  progress  and  corporate  direction.

(d)     The  Advisor will be required to interact with both treating Physicians,
current  and  potential  patients  to  determine  the  scope  of  treatments,
documentation  policies,  proof of efficacy issues, as well as develop strategic
alliances  with  other  organizations and individuals outside of the Company for
the advancement of our knowledge and expertise in the treatment of patients with
our  various  stem  cell  Products.

(e)     The  Advisor's  roll will be to make sure that the Company will maintain
its competitive edge both globally and in the United States in the field of stem
cell  treatments  and  research.

3.     COMPENSATION.

     The  Company  shall  issue  ten thousand (10,000) shares of Rule 144 common
stock  of  the  Company  to the Advisor as compensation for the initial one year
term  of  this  agreement,  as  follows:

     (a)     Thirty  days  after  the  execution  of this agreement, the Company
shall  issue  five  thousand  (5,000) shares of common stock under rule 144, and

     (b)     Six months after the execution of this agreement, the Company shall
issue  the  remaining  five thousand (5,000) shares common stock under rule 144.

     (c)     Compensation  for  successive renewal years under the terms of this
Agreement  shall  be  issued  at thirty days and six months after renewal in two
increments  of  five  thousand  shares  of  rule  144  common  stock.

4.     TERM.

This  Agreement will become effective on the date of execution and will continue
in  full  force  and  effect for a minimum period of one (1) year and thereafter
from year to year unless and until terminated by a party in accordance with this
Agreement.

5.     TERMINATION.

During  the  minimum  period  of  one  (1)  year,  either  party may immediately
terminate  this  Agreement  for  cause,  upon  written  notice for any breach of
contract,  if  the other party does not cure a material breach of this Agreement
within  thirty  (30)  days  of  receipt of written notice detailing such breach.

After  the  expiration  of  one  (1)  year  from  the  date of execution of this
agreement,  either  party  may  terminate  this  Agreement without cause and for
convenience with fourteen (14) days prior written notice to the other party.  At
any time, the parties may mutually agree in writing to terminate this Agreement.

6.     CONFIDENTIALITY.

          The  Advisor  shall  not  use  or divulge or communicate to any person
(other  than  those  whose  province  it  is to know the same or as permitted or
contemplated  by  this Agreement or with the written approval of the other party
or  as  may  be  required  by  law):
(i)                 any  Confidential  Company  Information;  or
(ii)                any  of  the  terms  of  this  Agreement

     The Advisor shall prevent the unauthorized publication or disclosure of any
such  information, materials or documents and ensure that any person to whom the
information,  materials  or  documents  are  disclosed is aware that the same is
confidential  and  is  covered  by  a  similar duty to maintain confidentiality.
     The  Advisor  shall  ensure  that  any  employees,  consultants,  agents or
advisors  are  aware  of  and comply with the confidentiality and non-disclosure
provisions contained in this Section and shall indemnify the Company against any
loss  or damage which the Company may sustain or incur as a result of any breach
of  the  terms  hereof  by the Advisor, or any employees, consultants, agents or
advisors.

     CONFIDENTIAL  INFORMATION.

     The Advisor shall not directly or indirectly, communicate, disclose or
divulge to any person or entity, or use for their own benefit or the benefit of
any person or entity, any knowledge or information which the Advisor may have
acquired, no matter from whom or on what matter such knowledge or information
may have been acquired from the Company.
These  provisions shall survive the expiration or termination of this Agreement.

7.     COVENANT  NOT  TO  COMPETE.

     The  Advisor,  during  the Term hereof, and for an additional period of two
years  thereafter  (the  ``Non-competition  Term''),  may  not:

(a)     Engage  or  participate  in or become employed by, or render advisory or
other  services  to,  any  business entity that competes with the Company in the
Ukraine  or  the  Dominican  Republic.

     If  the  foregoing  provision  is determined to be invalid by reason of the
length  of  any  period  or the size of the area set forth, such period of time,
such  area  or both will be considered to be reduced to a period of time or area
that  will  cure  such  invalidity.

(b)     Directly  or  indirectly  solicit  or induce any person, corporation, or
other  entity  that is a customer of the Company at the time of the execution of
this  agreement  or  that  was a customer at any time within the one-year period
immediately preceding such termination to become a customer of any other person,
corporation,  or  other  entity  competing  with  the Company or its Parent. The
Advisor  further  agrees  that  he  or  she  will  not approach any such person,
corporation,  or  other  entity  for  such  purposes.

(c)     Directly  or  indirectly solicit or induce any person who is an Employee
of  the  Company  or  its  Parent  to  become  employed  by  any person, firm or
corporation  competing  with the Company or its Parent, or approach any Employee
for  such  purpose.

(d)     Disclose  any  proprietary or confidential information of the Company or
its Parent relating to (i) the customers, clients, employees and accounts of the
Company  or  its  Parent,  including  but  not  limited  to  the identity of the
Company's  or  its  Parent's  customers  if  such  identity  is  proprietary  or
confidential;  (ii)  the  Company's  or  its Parent's business methods, systems,
plans,  policies,  and personnel; or (iii) the technical data, trade secrets, or
know-how  of the Company or its Parent, including, but not limited to, research,
product  plans, products, services, markets, software, developments, inventions,
processes,  formulas,  technology,  designs,  drawings,  engineering,  hardware,
configuration  information,  marketing,  finances  or other business information
disclosed  by  the Company or its Parent, either directly or indirectly, whether
in  writing,  orally  or  by  drawings  or  inspection  of  parts  or equipment.

8.     ARBITRATION  OF  DISPUTES.

(a)     The  Company  and  the  Advisor  agree  that  any dispute or controversy
arising  out  of or relating to any interpretation, construction, performance or
breach  of  this  Agreement,  will  be  settled  by  arbitration  to  be held in
Philadelphia  County,  Pennsylvania, in accordance with the rules then in effect
of the American Arbitration Association. The arbitrator may grant injunctions or
other  relief  in  the  dispute  or  controversy.

(b)     The  decision of the arbitrator will be final, conclusive and binding on
the  parties  to  the  arbitration.  Judgment may be entered on the arbitrator's
decision  in  any  court  of competent jurisdiction. The Company and The Advisor
will each pay one-half of the cost and expenses of the arbitration and each will
separately  pay  its  respective  counsel  fees  and  expenses.

     The  Advisor  acknowledges  that the services to be rendered by the Advisor
are  of  a  special, unique and extraordinary character, and in  connection with
such services, the Advisor will have access to confidential information vital to
the  Company's  and  its  Parent's  business.

By  reason  of  this, the Advisor agrees that if the Advisor violates any of the
provisions  of  this Agreement with respect to non-competition, diversion of the
Company's and its Parent's clients or employees, or confidentiality, the Company
and the Parent would sustain irreparable harm, and therefore, in addition to any
other  remedies  that  the Company and Parent may have under this Agreement, the
Company  and  Parent  will  be  entitled  to  apply  to  any  court of competent
jurisdiction  for  equitable  relief,  including  specific  performance  and
injunctions  restraining  the  Advisor  from  committing  or continuing any such
violation  of  this  Agreement.

(b)     The  Advisor  further  agrees  that  no  bond  or other security will be
required  in  obtaining  equitable relief and the Advisor hereby consents to the
issuance  of  an  injunction  and  to  the  ordering  of  specific  performance.

(c)     The  Advisor  further  agrees  that  he  will  be  required  to  sign an
INFORMATION & PRODUCT EVALUATION AND NON-DISCLOSURE AGREEMENT in order to accept
the  position  on  the  SCTI  Medical  and  Scientific  Advisory  Board.

9.     INDEMNITY

     The  Advisor shall and does hereby agree to defend, indemnify, release, and
save  harmless  the  Company,  or  companies  agents, representatives, servants,
employees,  attorneys,  and assigns from and against any and all suits, actions,
judgments,  damages,  costs, expenses, and attorneys fees incurred in defense of
any  action  or  proceeding  arising  out  of  the performance of this agreement

 10.     NOTICES.

     Any notice, request, demand or other communication required or permitted to
be  given under this Agreement will be sufficient if in writing and if delivered
personally, or sent by certified or registered mail as follows (or to such other
addressee or address as will be set forth in a notice given in the same manner):

If  to  the  Advisor:  Dr.  Weiwen  Deng,  MD.

____________________________________

and
____________________________________

If  to  the  Company:

Calvin  C.  Cao
CEO/Chairman
Stem  Cell  Therapy  International  Inc.
2203  North  Lois  Avenue,  9th  Floor,  Suite  #901
Tampa,  FL  33607

     Any  such notice will be deemed to be given on the date delivered or mailed
in  the  manner  provided  above.

 11.     WAIVER  OF  BREACH.

     The waiver by the Company or by the Advisor of a breach of any provision of
this Agreement by the other party will not operate, or be construed, as a waiver
of  any  other  breach  of  such  other  party.

12.     ASSIGNMENT.

     This  Agreement  will  inure  to  the  benefit of, and be binding upon, the
Company,  its  successors  and  assigns.  This  Agreement will be binding on the
Advisor,  the  Advisor's  heirs,  executors  or  administrators,  and  legal
representatives.  However,  this Agreement will not be assignable by the Advisor
nor  may  the  obligations  of the Advisor be delegated, without express written
consent  of  the  Company.

 13.     ENTIRE  AGREEMENT.

     This  Agreement  represents  the  entire  understanding  of the parties and
supersedes all previous agreements, oral or written, between the parties and any
modification  of  the  agreement must be in writing and executed by the parties.
This  is  a personal services contract and the Advisor may not assign any rights
or  delegate  any  duties  of  the  Advisor  under  this  agreement.

 14.     APPLICABLE  LAW.

     The  parties  agree  that  this  Agreement  will  be construed and enforced
pursuant  to  the  laws  of  the  Commonwealth  of  Pennsylvania.

     IN WITNESS WHEREOF, the parties have set their hands as of the day and year
first  above  written.

Stem Cell Therapy International, Inc.          SCTI Medical and Scientific Board
Advisor

By:                              BY:  ____________________________
Calvin  C.  Cao,  CEO/Chairman               Advisor,  Dr.  Weiwen  Deng,  MD.STEM CELL THERAPY INTERNATIONAL, INC.

              SCTI MEDICAL AND SCIENTIFIC ADVISORY BOARD AGREEMENT

     THIS  AGREEMENT is made this 24th day of October, 2005, by and between STEM
CELL THERAPY INTERNATIONAL, INC.; a corporation duly incorporated under the laws
of Nevada, with its principal office located at 2203 North Lois Ave., 9th Floor,
Tampa,  Florida  33594 ("the Company''), and DR. JORGE QUINTERO, MD. as a member
of  the  SCTI  Medical  and  Scientific  Advisory Board, herein ("the Advisor").

     In  consideration  of the mutual agreements contained in this document, the
parties,  intending  to  be  legally  bound,  agree  as  follows:

 1.     INDEPENDENT  CONTRACTOR.

     The  Advisor  will  be an independent contractor and not an Employee of the
Company  and  will  determine  will  determine  the  method  of operation in the
performance  of  allo  (human)  stem  cell  biological  solution  and  tissue
transplantations  and/or  any  other  type of required stem cell transplantation
therapy.

     The  Advisor  will not be entitled to receive any compensation, commissions
or  benefits  other  than  those  expressly  provided  in  this  Agreement.

 2.     SCOPE  OF  DUTIES.

(a)     The  Advisor  certifies  that  there  are  no  outstanding agreements or
obligations  that conflict with any of the provisions of this Agreement, or that
would  preclude  or  in  any  way  compromise the Advisor in compliance with the
provisions  hereof.

(b)     The  Advisor agrees to actively participate in the Company's Medical and
Scientific  Advisory Board and to review patient's medical charts and records as
provided  by  the  Company and to provide the Company a written report detailing
recommendations  for  the  appropriate  course  of  stem cell therapy treatment.

(c)     The  Advisor agrees to participate in conference calls and meetings with
the  SCTI  Corporate  Officers  and  other  members of the Company's Medical and
Scientific  Advisory  Board  when his/her schedule allows, to discuss the latest
technology  in  stem  cell  treatments  and  shall  contribute  with  his/her
recommendations  on  future  progress  and  corporate  direction.

(d)     The  Advisor will be required to interact with both treating Physicians,
current  and  potential  patients  to  determine  the  scope  of  treatments,
documentation  policies,  proof of efficacy issues, as well as develop strategic
alliances  with  other  organizations and individuals outside of the Company for
the advancement of our knowledge and expertise in the treatment of patients with
our  various  stem  cell  Products.

(e)     The  Advisor's  roll will be to make sure that the Company will maintain
its competitive edge both globally and in the United States in the field of stem
cell  treatments  and  research.

3.     COMPENSATION.

     The  Company  shall  issue  ten thousand (10,000) shares of Rule 144 common
stock  of  the  Company  to the Advisor as compensation for the initial one year
term  of  this  agreement,  as  follows:

     (a)     Thirty  days  after  the  execution  of this agreement, the Company
shall  issue  five  thousand  (5,000) shares of common stock under rule 144, and

     (b)     Six months after the execution of this agreement, the Company shall
issue  the  remaining  five thousand (5,000) shares common stock under rule 144.

     (c)     Compensation  for  successive renewal years under the terms of this
Agreement  shall  be  issued  at thirty days and six months after renewal in two
increments  of  five  thousand  shares  of  rule  144  common  stock.

4.     TERM.

This  Agreement will become effective on the date of execution and will continue
in  full  force  and  effect for a minimum period of one (1) year and thereafter
from year to year unless and until terminated by a party in accordance with this
Agreement.

5.     TERMINATION.

During  the  minimum  period  of  one  (1)  year,  either  party may immediately
terminate  this  Agreement  for  cause,  upon  written  notice for any breach of
contract,  if  the other party does not cure a material breach of this Agreement
within  thirty  (30)  days  of  receipt of written notice detailing such breach.

After  the  expiration  of  one  (1)  year  from  the  date of execution of this
agreement,  either  party  may  terminate  this  Agreement without cause and for
convenience with fourteen (14) days prior written notice to the other party.  At
any time, the parties may mutually agree in writing to terminate this Agreement.

6.     CONFIDENTIALITY.

          The  Advisor  shall  not  use  or divulge or communicate to any person
(other  than  those  whose  province  it  is to know the same or as permitted or
contemplated  by  this Agreement or with the written approval of the other party
or  as  may  be  required  by  law):
(i)                 any  Confidential  Company  Information;  or
(ii)                any  of  the  terms  of  this  Agreement

     The Advisor shall prevent the unauthorized publication or disclosure of any
such  information, materials or documents and ensure that any person to whom the
information,  materials  or  documents  are  disclosed is aware that the same is
confidential  and  is  covered  by  a  similar duty to maintain confidentiality.
     The  Advisor  shall  ensure  that  any  employees,  consultants,  agents or
advisors  are  aware  of  and comply with the confidentiality and non-disclosure
provisions contained in this Section and shall indemnify the Company against any
loss  or damage which the Company may sustain or incur as a result of any breach
of  the  terms  hereof  by the Advisor, or any employees, consultants, agents or
advisors.

     CONFIDENTIAL  INFORMATION.

     The Advisor shall not directly or indirectly, communicate, disclose or
divulge to any person or entity, or use for their own benefit or the benefit of
any person or entity, any knowledge or information which the Advisor may have
acquired, no matter from whom or on what matter such knowledge or information
may have been acquired from the Company.
These  provisions shall survive the expiration or termination of this Agreement.

7.     COVENANT  NOT  TO  COMPETE.

     The  Advisor,  during  the Term hereof, and for an additional period of two
years  thereafter  (the  ``Non-competition  Term''),  may  not:

(a)     Engage  or  participate  in or become employed by, or render advisory or
other  services  to,  any  business entity that competes with the Company in the
Ukraine  or  the  Dominican  Republic.

     If  the  foregoing  provision  is determined to be invalid by reason of the
length  of  any  period  or the size of the area set forth, such period of time,
such  area  or both will be considered to be reduced to a period of time or area
that  will  cure  such  invalidity.

(b)     Directly  or  indirectly  solicit  or induce any person, corporation, or
other  entity  that is a customer of the Company at the time of the execution of
this  agreement  or  that  was a customer at any time within the one-year period
immediately preceding such termination to become a customer of any other person,
corporation,  or  other  entity  competing  with  the Company or its Parent. The
Advisor  further  agrees  that  he  or  she  will  not approach any such person,
corporation,  or  other  entity  for  such  purposes.

(c)     Directly  or  indirectly solicit or induce any person who is an Employee
of  the  Company  or  its  Parent  to  become  employed  by  any person, firm or
corporation  competing  with the Company or its Parent, or approach any Employee
for  such  purpose.

(d)     Disclose  any  proprietary or confidential information of the Company or
its Parent relating to (i) the customers, clients, employees and accounts of the
Company  or  its  Parent,  including  but  not  limited  to  the identity of the
Company's  or  its  Parent's  customers  if  such  identity  is  proprietary  or
confidential;  (ii)  the  Company's  or  its Parent's business methods, systems,
plans,  policies,  and personnel; or (iii) the technical data, trade secrets, or
know-how  of the Company or its Parent, including, but not limited to, research,
product  plans, products, services, markets, software, developments, inventions,
processes,  formulas,  technology,  designs,  drawings,  engineering,  hardware,
configuration  information,  marketing,  finances  or other business information
disclosed  by  the Company or its Parent, either directly or indirectly, whether
in  writing,  orally  or  by  drawings  or  inspection  of  parts  or equipment.

8.     ARBITRATION  OF  DISPUTES.

(a)     The  Company  and  the  Advisor  agree  that  any dispute or controversy
arising  out  of or relating to any interpretation, construction, performance or
breach  of  this  Agreement,  will  be  settled  by  arbitration  to  be held in
Philadelphia  County,  Pennsylvania, in accordance with the rules then in effect
of the American Arbitration Association. The arbitrator may grant injunctions or
other  relief  in  the  dispute  or  controversy.

(b)     The  decision of the arbitrator will be final, conclusive and binding on
the  parties  to  the  arbitration.  Judgment may be entered on the arbitrator's
decision  in  any  court  of competent jurisdiction. The Company and The Advisor
will each pay one-half of the cost and expenses of the arbitration and each will
separately  pay  its  respective  counsel  fees  and  expenses.

     The  Advisor  acknowledges  that the services to be rendered by the Advisor
are  of  a  special, unique and extraordinary character, and in  connection with
such services, the Advisor will have access to confidential information vital to
the  Company's  and  its  Parent's  business.

By  reason  of  this, the Advisor agrees that if the Advisor violates any of the
provisions  of  this Agreement with respect to non-competition, diversion of the
Company's and its Parent's clients or employees, or confidentiality, the Company
and the Parent would sustain irreparable harm, and therefore, in addition to any
other  remedies  that  the Company and Parent may have under this Agreement, the
Company  and  Parent  will  be  entitled  to  apply  to  any  court of competent
jurisdiction  for  equitable  relief,  including  specific  performance  and
injunctions  restraining  the  Advisor  from  committing  or continuing any such
violation  of  this  Agreement.

(b)     The  Advisor  further  agrees  that  no  bond  or other security will be
required  in  obtaining  equitable relief and the Advisor hereby consents to the
issuance  of  an  injunction  and  to  the  ordering  of  specific  performance.

(c)     The  Advisor  further  agrees  that  he  will  be  required  to  sign an
INFORMATION & PRODUCT EVALUATION AND NON-DISCLOSURE AGREEMENT in order to accept
the  position  on  the  SCTI  Medical  and  Scientific  Advisory  Board.

9.     INDEMNITY

     The  Advisor shall and does hereby agree to defend, indemnify, release, and
save  harmless  the  Company,  or  companies  agents, representatives, servants,
employees,  attorneys,  and assigns from and against any and all suits, actions,
judgments,  damages,  costs, expenses, and attorneys fees incurred in defense of
any  action  or  proceeding  arising  out  of  the performance of this agreement

 10.     NOTICES.

     Any notice, request, demand or other communication required or permitted to
be  given under this Agreement will be sufficient if in writing and if delivered
personally, or sent by certified or registered mail as follows (or to such other
addressee or address as will be set forth in a notice given in the same manner):

If  to  the  Advisor:  Dr.  Jorge  Quintero,  MD.

____________________________________

and
____________________________________

If  to  the  Company:

Calvin  C.  Cao
CEO/Chairman
Stem  Cell  Therapy  International  Inc.
2203  North  Lois  Avenue,  9th  Floor,  Suite  #901
Tampa,  FL  33607

     Any  such notice will be deemed to be given on the date delivered or mailed
in  the  manner  provided  above.

 11.     WAIVER  OF  BREACH.

     The waiver by the Company or by the Advisor of a breach of any provision of
this Agreement by the other party will not operate, or be construed, as a waiver
of  any  other  breach  of  such  other  party.

12.     ASSIGNMENT.

     This  Agreement  will  inure  to  the  benefit of, and be binding upon, the
Company,  its  successors  and  assigns.  This  Agreement will be binding on the
Advisor,  the  Advisor's  heirs,  executors  or  administrators,  and  legal
representatives.  However,  this Agreement will not be assignable by the Advisor
nor  may  the  obligations  of the Advisor be delegated, without express written
consent  of  the  Company.

 13.     ENTIRE  AGREEMENT.

     This  Agreement  represents  the  entire  understanding  of the parties and
supersedes all previous agreements, oral or written, between the parties and any
modification  of  the  agreement must be in writing and executed by the parties.
This  is  a personal services contract and the Advisor may not assign any rights
or  delegate  any  duties  of  the  Advisor  under  this  agreement.

 14.     APPLICABLE  LAW.

     The  parties  agree  that  this  Agreement  will  be construed and enforced
pursuant  to  the  laws  of  the  Commonwealth  of  Pennsylvania.

     IN WITNESS WHEREOF, the parties have set their hands as of the day and year
first  above  written.

Stem Cell Therapy International, Inc.          SCTI Medical and Scientific Board
Advisor

By:                              BY:  ____________________________
Calvin  C.  Cao,  CEO/Chairman               Advisor,  Dr.  Jorge  Quintero, MD.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]